Recombinant human thrombopoietin biosimilar (Biolotus)

重组人血小板生成素生物类似药 (Biolotus)

Report date: 2022/05/20 09:48:35

Base Information

Drug NameRecombinant human thrombopoietin biosimilar (Biolotus)
Drug Alias NameTPO-Biolotus重组人血小板生成素生物仿制药 (Biolotus)rhTPO-BiolotusZypotin-TPO
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryBrazil
Original Approved Date2015/01/01
Country/TerritoryBrazil
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiolotus
China Registration ClassN/A

Develop Information

Active CompaniesBiolotus
Inactive CompaniesN/A
Active IndicationsThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AC02
Related LinksN/A